STMicroelectronics reveals advanced ultra-low-power STM32 microcontrollers for industrial, medical, smart-metering, and consumer applications

STMicroelectronics reveals advanced ultra-low-power STM32 microcontrollers for industrial, medical, smart-metering, and consumer applications

P4616S — Mar 19 2024 — STM32U0 MCUs_IMAGE STM32U0 MCUs STMicroelectronics reveals advanced ultra-low-power STM32 microcontrollers for industrial, medical, smart-metering, and consumer applications New flagship in ultra-low-power consumes less, delivers more at effective cost Geneva, Switzerland, March 19, 2024 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has introduced a new generation of energy-conscious and cost-effective microcontrollers (MCUs) that can reduce energy consumption by up to 50% compared to previous product generations. This enables less frequent battery replacements, minimizes the impact of discarded batteries, and allows more designs to go battery free running solely from an energy-harvesting system such as a small...

Continue reading

The Novo Nordisk Foundation chooses Eviden to build “Gefion” in Denmark, one of the world’s most powerful AI supercomputers

The Novo Nordisk Foundation chooses Eviden to build “Gefion” in Denmark, one of the world’s most powerful AI supercomputers

Press Release The Novo Nordisk Foundation chooses Eviden to build “Gefion” in Denmark, one of the world’s most powerful AI supercomputers Paris, France – March 19, 2024 – Eviden, the Atos Group business leading in advanced computing, today announces a new contract with the Danish Centre for AI Innovation, owned by the Novo Nordisk Foundation and the Export and Investment Fund of Denmark, to construct a state-of-the-art AI supercomputer in Denmark. The supercomputer is designed to cater to large-scale projects that utilize artificial intelligence and prioritize the highest level of security to support Danish data sovereignty. The new supercomputer is expected to be one of the most powerful AI supercomputers in the world. Its goal is to accelerate research and innovation in various fields such as healthcare, life sciences, and the green...

Continue reading

<div>Engage with Pluri's Talent: Exciting Conference Appearances Ahead</div>

Engage with Pluri’s Talent: Exciting Conference Appearances Ahead

HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) — Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences.    Conference: Bio-Europe SpringDate: March 18-20, 2024Location: BarcelonaPluri’s Chief Business Development Officer-Pharma Efrat Kaduri will attend the event. BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings. Conference: Advanced Therapies 2024Date: March 19-20, 2024Location: LondonPluri’s Chief Technology Officer Lior Raviv will participate in a panel discussion...

Continue reading

Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our fifth VLGC newbuilding

Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our fifth VLGC newbuilding

Hamilton, BermudaMarch 19, 2024 Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) announce today the successful sale of newbuilding hull 2367 with intended name Avance Castor for a cash consideration of $120 million less broker commission as previously announced in a press release dated December 8, 2023. The Company expect to record a book gain on sale and cash release following repayment of bank financing of $36 million and $61 million respectively. The sale of the sister ship, newbuilding hull 2368 with intended name Avance Pollux, is scheduled to take place in the first half of May 2024. This sale is also expected to result in a book gain and cash release of $36 million and $60 million respectively. For further queries, please contact:Media contact: Øystein Kalleklev, CEO Tel: +47 23 11 40 00 Investor and Analyst contact:Randi...

Continue reading

Kauno energija, AB. Regarding information published in the media

Kauno energija, AB. Regarding information published in the media

In response to the information published in the media about the alleged misappropriation of funds from the company, AB Kauno energija informs that at the end of 2023, funds were fraudulently transferred from the company’s account to the accounts of third parties. Thanks to the prompt actions of the company, financial institutions and law enforcement, a large part of the funds has already been returned to the company’s account. This event does not have a significant impact on the company’s activities. The law enforcement authorities are currently conducting a pre-trial investigation. Virgilijus Motiejūnas Chief Financial Officer, tel. +37068789362

Continue reading

INVL Baltic Farmland plans to earn EUR 420 thousand net profit in 2024

INVL Baltic Farmland plans to earn EUR 420 thousand net profit in 2024

The board of INVL Baltic Farmland, AB, a company investing in agricultural land, approved its activity forecasts for 2024. Consolidated revenues of INVL Baltic Farmland are forecasted at EUR 835 thousand and net profit should amount to EUR 420 thousand. These predictions are based on the assumption that during 2024 the value of the Company’s land holdings will not change. Also there will be no purchases or sales of land, and there will be no changes in provisions for receivables and no impact of tenant debts on the size of the administration fee. INVL Baltic Farmland and its subsidiaries own approximately 3,000 hectares of agricultural land in Lithuania which is rented out to agriculture companies and farmers. Additional information: The board of INVL Baltic Farmland, a company that invests in agricultural land, approved the company’s...

Continue reading

<div>Boyden Expands Presence in Energy Sector with Acquisition of FWB's Energy Practice in Scotland</div>

Boyden Expands Presence in Energy Sector with Acquisition of FWB’s Energy Practice in Scotland

Move marks a significant expansion for Boyden in the energy sector and underscores its commitment to providing unparalleled service to clients worldwide. ABERDEEN, Scotland, March 19, 2024 (GLOBE NEWSWIRE) — Boyden, the global leadership and talent advisory firm, announces the acquisition of FWB’s Energy Practice in Scotland, United Kingdom, effective March 1st, 2024. With this acquisition, Boyden in the United Kingdom will be operating from new offices in Aberdeen, adding to its UK presence in London. The acquisition further strengthens Boyden’s industrial practice and enhances its ability to serve clients globally in the oil, gas, mining, and renewables industries. Nick Robeson, Managing Partner for Boyden in the UK & Ireland, expressed his appreciation to the FWB team involved in the acquisition and stated,...

Continue reading

IBA signs contract to install a Be-Efficient irradiation solution in Germany

IBA signs contract to install a Be-Efficient irradiation solution in Germany

Louvain-la-Neuve, Belgium, March 19, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today it has signed a contract for the installation of a Be-Efficient electron beam irradiation solution equipped with two Rhodotron® accelerators in Germany. This Be-Efficient electron beam solution includes two Rhodotron® accelerators, a Beagle® production line control system and a Building Safety System. The Be-Efficient solution will be used for e-beam irradiation for polymer crosslinking applications, which enhances the resistance of polymers. The typical price for a Be-Efficient irradiation solution ranges from EUR 11 million to EUR 18 million, depending on the configuration and options. In addition to this contract,...

Continue reading

WISe.ART to Host the Prestigious ProArte y Cultura Mayte Spínola Gold Medals 2023 at the Iconic Nasdaq Building in New York City on April 1, 2024

WISe.ART to Host the Prestigious ProArte y Cultura Mayte Spínola Gold Medals 2023 at the Iconic Nasdaq Building in New York City on April 1, 2024

New York, NY & Madrid, Spain, March 19, 2024 (GLOBE NEWSWIRE) — WISe.ART to Host the Prestigious ProArte y Cultura Mayte Spínola Gold Medals 2023 at the Iconic Nasdaq Building in New York City on April 1, 2024 New York / Madrid – March 19, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, operating as a holding company, in partnership with Grupo Pro Arte y Cultura, announced that its subsidiary WISe.ART is will be hosting the Mayte Spínola Gold Medals 2023, in its special 10th Edition, at the Nasdaq MarketSite located at 4 Times Square (43rd & Broadway), in the heart of New York City, on April 1, 2024. This year’s event is particularly momentous as it celebrates the 80th anniversary of Mayte Spínola,...

Continue reading

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced key updates of the inverse vaccine platform with the potential to treat autoimmune diseases at the 7th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases. At the conference, Nykode demonstrated for the first time a significant effect in a therapeutic setting in a preclinical model for Multiple Sclerosis (MS) with its inverse vaccine platform. The data also illustrate the strong contribution of the specific targeting unit and confirm that...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.